• 1
    Keating MJ,Flinn I,Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002; 99: 35543561.
  • 2
    Lundin J,Kimby E,Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002; 100: 768773.
  • 3
    Slobedman B,Mocarski ES,Arvin AM,Mellins ED,Abendroth A. Latent cytomegalovirus down-regulates major histocompatibility complex Class II expression on myeloid progenitors. Blood. 2002; 100: 28672873.
  • 4
    Gandhi MK,Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004; 4: 725738.
  • 5
    Ferrajoli A,O'Brien SM,Cortes JE, et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer. 2003; 98: 773778.
  • 6
    Lundin J,Hagberg H,Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003; 101: 42674272.
  • 7
    Nguyen DD,Cao TM,Dugan K, et al. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma. 2002; 3: 105110.
  • 8
    Laurenti L,Piccioni P,Cattani P, et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica. 2004; 89: 12481252.
  • 9
    Faderl S,Thomas DA,O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003; 101: 34133415.
  • 10
    Lundin J,Porwit-MacDonald A,Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, Campath-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia. 2004; 18: 484490.
  • 11
    Chakrabarti S,Mackinnon S,Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002; 99: 43574363.
  • 12
    Lamba R,Carrum G,Myers GD, et al. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with alemtuzumab. Bone Marrow Transplant. 2005; 36: 797802.
  • 13
    Ng AP,Worth L,Chen L, et al. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. Haematologica. 2005; 90: 16721679.
  • 14
    Lin TS,Flinn IW,Lucas MS, et al. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. Leukemia. 2005; 19: 12071210.
  • 15
    O'Brien SM,Kantarjian HM,Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 2003; 98: 26572663.
  • 16
    van Dorp WT,Vlieger A,Jiwa NM, et al. The polymerase chain reaction, a sensitive and rapid technique for detecting cytomegalovirus infection after renal transplantation. Transplantation. 1992; 54: 661664.
  • 17
    Eriksson BM,Wirgart BZ,Claesson K, et al. A prospective study of rapid methods of detecting cytomegalovirus in the blood of renal transplant recipients in relation to patient and graft survival. Clin Transplant. 1996; 10: 494502.
  • 18
    Hadaya K,Wunderli W,Deffernez C, et al. Monitoring of cytomegalovirus infection in solid-organ transplant recipients by an ultrasensitive plasma PCR assay. J Clin Microbiol. 2003; 41: 37573764.
  • 19
    Van der Giessen M,van den Berg AP,van der Bij W, et al. Quantitative measurement of cytomegalovirus-specific IgG and IgM antibodies in relation to cytomegalovirus antigenaemia and disease activity in kidney recipients with an active cytomegalovirus infection. Clin Exp Immunol. 1990; 80: 5661.
  • 20
    Becker BN,Becker YT,Heisey DM, et al. The impact of hypoalbuminemia in kidney-pancreas transplant recipients. Transplantation. 1999; 68: 7275.